Magnificent 7 Crush EU Giants—Jamie Dimon Tells Europe: 'You're Losing' Jamie Dimon warns Europe is falling behind the U.S. economically. Market caps show an even wider gap as U.S. tech giants dominate.
Options Corner: Bullish Traders Eye Eli Lilly As Market Signals Hint At A Turnaround While Eli Lilly has struggled in the past year due to competitive pressures, the statistical winds may finally favor LLY stock.
Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment? The company announced a new drug that uses the same mechanism as Eli Lilly's retatrutide.
Trump Vows To Cut 'The Best Deal' On Drug Prices. What To Expect. President Donald Trump, ever the negotiator, is angling to lower drug prices through his Most Favored Nation policy.
Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug? Biogen is hoping to top its own spinal muscular atrophy treatment, Spinraza, with a next-generation version.
Analyst Flags Septerna As Undervalued Biotech Play With Significant Upside Septerna gains Buy rating as HC Wainwright highlights undervaluation, strong pipeline, and key partnership with Novo Nordisk in metabolic diseases.
Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars Exelixis' STELLAR-303 trial shows zanzalintinib plus Tecentriq improved survival in colorectal cancer, with no new safety concerns reported.
Exelixis Catapults 14% On Positive Results For Next-Gen Colon Cancer Drug Shares surged Monday after the company said its next-generation cancer drug showed promise in a colon cancer study.
MAIA’s New Agreement With Big Pharma Roche Turns Retail Investors Bullish As Stock Soars The agreement aims to support future studies investigating the combination of MAIA’s Ateganosine and Roche’s checkpoint inhibitor, Atezolizumab, for safe and effective cancer treatments.
Roche Stock Slides After Failed Blood Cancer Trial With AbbVie, But Parkinson’s Therapy Progress Boosts Retail Mood The Swiss pharma giant advanced its anti-alpha-synuclein antibody prasinezumab to the next stage based on promising Phase IIb data.
Sarepta Therapeutics Stock Plummets Over 40% On Second Fatal Case Linked To Its Gene Therapy Sarepta suspends Elevidys use in non-ambulatory Duchenne patients after two liver failure deaths, triggering FDA review and clinical trial pause.
Eli Lilly's Obesity Drug Success Spurs Japanese Biotech's Anti-Muscle-Wasting Combo Therapy Chugai plans to pair its muscle-preserving drug with Eli Lilly's orforglipron, addressing muscle loss in obesity care as the market expands rapidly.
Jazz Pharma's Zepzelca Combo Shows Survival Edge In Lung Cancer Study Jazz Pharma's Zepzelca plus Tecentriq significantly improved survival in a Phase 3 study for extensive-stage small-cell lung cancer patients.
How AstraZeneca Is Playing Its Cancer Cards To Become An $80 Billion Pharma Three new cancer drugs could help make a dent in the company's ambitious plans for 2030.
Roche's Multiple Sclerosis Drug Shows Low Disease Activity Over Two Years Roche shares new data showing its MS drug fenebrutinib maintained low relapse rates and no disability progression in patients over 96 weeks.
Roche Gets Positive Opinion For Approval Of Cancer Therapy In EU: Retail Yet To React The company said that the European Commission is expected to make a decision soon regarding the approval for Itovebi.
Novo Nordisk Sheds 4% After Ousting CEO As Eli Lilly Rivalry Slams Stock Price Novo Nordisk said Friday it will replace its CEO, citing a sharp tumble for Novo shares amid growing competition.
Merck Data Shows Positive Outcomes For Ovarian Cancer Patients Treated With Keytruda Merck's Phase 3 trial of Keytruda plus chemo met progression-free survival and overall survival goals in platinum-resistant ovarian cancer, including patients with PD-L1–positive tumors.
Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030 Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job creation across states.
FDA Fast-Tracks AbbVie's New Lung Cancer Therapy Emrelis For Tough Lung Cancer Cases FDA grants accelerated approval to AbbVie's Emrelis for c-Met overexpressing NSCLC; siRNA partnership with ADARx includes $335 million upfront.
